🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Denmark / NCT07304375
Recruiting Not applicable

Effects of Exercise and Sleep on Motor Learning and Functional Abilities in Multiple Sclerosis

NCT07304375 · tracked via the Priya Life Science Denmark tracker
Phase
Not applicable
Started
2025-12-01
Last updated
2026-01-08

Condition(s) studied

ExerciseSleepMotor LearningMemoryMultiple Sclerosis

Investigational drug(s) / intervention(s)

Aerobic ExerciseDaytime Sleep - Nap

Aerobic Exercise: The Aerobic Exercise Intervention consists of 20 minutes of Graded Exercise Test (GXT) on an ergometer bike. The participants start with 5 minutes of warm-up. The wattload will then be increased until exhaustion.

Daytime Sleep - Nap: The Daytime sleep consists of a 30-minute nap after the acquisition of the visuomotor accuracy tracking task. The participants will be asked to rest in a supine position in a bed in a dark and quiet room.

Study summary

The ExSiMS study is a randomized, controlled crossover study including 20 individuals (18-70 years) diagnosed with relapsing remitting Multiple Sclerosis (MS) This project investigates, through behavioral and neurophysiological measurements, how aerobic exercise on an ergometer bike and sleep in the form of a nap and overnight sleep may enhance cortical motor skill learning evaluated by a complex hand motor skill test and thereby improve functional capacity in individuals with MS. Beyond the effect on motor skill learning, the project investigate the effect on electroencephalography (EEG) - electromyography (EMG) coherence.

The study hypothesizes that individuals with neurological conditions, such as multiple sclerosis (MS), may experience beneficial effects on specific motor rehabilitation through systematically planned cardiovascular exercise and sleep scheduling, due to positive impacts on memory consolidation.

Aims:

* Investigate the brain's neurophysiological responses and memory effects following a training intervention and, separately, sleep, in the form of a power nap, in individuals with MS.
* Examine whether these effects persist beyond the few days previously observed in healthy individuals by implementing a longer-term intervention.
* Explore whether the training effect is influenced by disease activity in the brain, such as during relapses and during immunosuppressive treatment.
* Assess whether the presence of abnormally reduced cognitive endurance (fatigue) affects the impact of the intervention involving exercise and sleep.

The study is based on documented positive effects of physical activity and sleep in both young and older adults, as well as in individuals recovering from stroke. The research thus offers promising perspectives for broader applications within neurorehabilitation, and particularly for MS, as the disease is associated with functional impairments. At the same time, both physical exercise and sleep represent meaningful interventions that should be thoughtfully integrated into rehabilitation strategies.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Competent individuals (aged 18-70) diagnosed with early relapsing-remitting MS * Expanded Disability Status Score, 1 \< EDSS \< 4.5 * MRC muscle strength ≥ 4+ in the dominant hand Exclusion Criteria: * Implanted devices, such as pacemakers or stimulators * Epilepsy or neuromuscular diseases

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Section of Movement and Neuroscience, Department of Nutrition, Exercise, and Sports, University of Copenhagen Copenhagen Denmark Not Yet Recruiting
Zealand University Hospital Roskilde Roskilde Denmark Recruiting

More Zealand University Hospital trials in Denmark

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07304375 on ClinicalTrials.gov ↗ ← All trials in Denmark